US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Candel Therapeutics Inc (CADL)
Candel Therapeutics Inc (CADL) ニュース

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CADL

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	06 : 20	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/31	05 : 30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/31	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/30	21 : 00	GlobeNewswire Inc.	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/24	20 : 30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/24	06 : 00	GlobeNewswire Inc.	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/22	21 : 00	GlobeNewswire Inc.	Candel Therapeutics to Present at the Jefferies Global Healthcare Conference	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/20	21 : 00	GlobeNewswire Inc.	Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/14	21 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/14	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/14	21 : 00	GlobeNewswire Inc.	Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	NASDAQ:CADL	Candel Therapeutics Inc
2024/04/25	21 : 00	GlobeNewswire Inc.	Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting	NASDAQ:CADL	Candel Therapeutics Inc
2024/04/11	22 : 00	GlobeNewswire Inc.	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer	NASDAQ:CADL	Candel Therapeutics Inc
2024/04/09	21 : 00	GlobeNewswire Inc.	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	NASDAQ:CADL	Candel Therapeutics Inc
2024/04/04	21 : 00	GlobeNewswire Inc.	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	NASDAQ:CADL	Candel Therapeutics Inc
2024/03/29	05 : 05	GlobeNewswire Inc.	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	NASDAQ:CADL	Candel Therapeutics Inc
2024/03/28	21 : 05	GlobeNewswire Inc.	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights	NASDAQ:CADL	Candel Therapeutics Inc
2024/03/06	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/03/06	06 : 30	GlobeNewswire Inc.	Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	NASDAQ:CADL	Candel Therapeutics Inc
2024/02/13	23 : 00	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CADL	Candel Therapeutics Inc
2024/02/13	21 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/02/13	21 : 30	GlobeNewswire Inc.	CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma	NASDAQ:CADL	Candel Therapeutics Inc
2024/02/05	22 : 00	GlobeNewswire Inc.	Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts	NASDAQ:CADL	Candel Therapeutics Inc
2024/01/19	22 : 30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CADL	Candel Therapeutics Inc
2024/01/13	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/01/03	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2023/12/12	22 : 58	Dow Jones News	Candel Therapeutics Shares Soar After FDA Fast Track of CAN-2409	NASDAQ:CADL	Candel Therapeutics Inc
2023/12/12	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2023/12/12	22 : 00	GlobeNewswire Inc.	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer	NASDAQ:CADL	Candel Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:CADL

1 2 3 4 5 6 7 次へ >>

Verizon Communications

Energy Select Sector SPDR

US Dollar vs Euro

US Dollar vs Yen

JP Morgan Chase

Financial Select Sector

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約